CVS Prioritizes Biosimilars Over Stelara July

CVS Health announced it will favor lower‑cost biosimilars instead of J&J’s Stelara on its formularies starting July 1.
Caremark will switch to Sandoz’s Pyzchiva and Biocon’s Yesintek biosimilars, with most members paying $0 out‑of‑pocket.
CVS Health shares dropped 1.4% following the announcement, while J&J rose 0.78% and Sandoz gained 4.93%.
Senior VP Joshua Fredell said the move will deliver significant savings and broader affordable access.